FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W164057601> ?p ?o ?g. }

• W164057601 endingPage "7" @default.
• W164057601 startingPage "611" @default.
• W164057601 abstract "As an effective regimen for isoniazid-resistant but rifampicin-susceptible tuberculosis (INHr-TB), the use of a 6-month three or four-drug treatment regimen including refampicin (or rifampin) and pyrazinamide has been recommended by many experts of the world. On the other hand, treatment regimen for rifampicin-resistant but isoniazide-susceptible tuberculosis (RFPr-TB) has not been well established because of the small number of such patients. In Japan the standard regimen has not been established even for INHr-TB, and the treatment has been done by each physician on the empirical bases.To determine the adequate therapy of INH-resistant TB or RFP-resistant TB.Retrospective cohort study. SUBJECTIVES: Hundred and eleven INHr-TB patients (4.9%) and 5 RFPr-TB patients (0.2%) out of 2252 new smear-positive tuberculosis patients who were admitted to our hospital from 1994 to 1998.Patients with previous tuberculosis history was found in 35 of 111 INHr-TB (31.5%) patients, of which 13 (37.1%) were re-treated within 3 years. On the other hand 146 patients (21.1%) of all new culture-positive tuberculosis patients (N = 690) treated in our hospital from 1997 to 1999 had the previous tuberculosis history of which only 8 patients (5.5%) were retreated within 3 years while 115 patients relapsed more than 10 years after the onset of previous tuberculosis history. The frequency of recurrence within 3 years after the onset of previous tuberculosis history was, significantly higher (p < 0.0001) in cases of INHr-TB (13/111 [11.7%]) than in cases of newly registered ones (8/690 [1.2%]), and the fact indicates that the incidence of tuberculosis recurrence was higher in INHr-TB patients than in pan-sensitive TB patients when the previous treatment was discontinued or insufficiently implemented. The resistance pattern of the INHr-strains were as follows. INH alone 40 (36.0%), SM-resistant 47 (42.3%), TH resistant 19 (17.1%), EB-resistant 18 (16.2%), KM-resistant 6 (5.4%), and others 3 (2.7%). Therefore the mean number (+/- SD) of resistant drugs excluding INH was 1.4 +/- 0.7. Eighteen out of 71 (25.4%) strains with low grade INH-resistance (0.1 microgram/ml complete resistance) had also TH-resistance, while only one out of 40 (2.5%) strains with high grade INH-resistance (1 microgram/ml resistance) was resistant to TH (p = 0.005). Of 111 INHr-TB patients, 9 patients (8.1%) discontinued treatment by themselves, 17 patients (15.3%) admitted to another hospital, and 17 patients (15.3%) died. The patients who died (age [M +/- SD] 66.4 +/- 14.0 yrs) were older than those who were alive (48.7 +/- 17.8, p < 0.001), and were too seriously ill to accept sufficient chemotherapy, and therefore their deaths were not considered to be related to INH resistance. The treatment outcomes of the remaining 68 patients who were followed in our hospital were summarized as follows. 1) Treatment failure occurred in 3 patients, of whom 2 patients could not be treated with full dose rifampicin in the initial phase of treatment because of side effects to liver or accompanying idiopathic thrombocytepenic purpura (ITP). Two out of these 3 patients developed multi-drug resistant tuberculosis (MDR-TB). Success rate of treatment was 65/68 (95.6%). 2) Alterations of regimens after knowing INHr-TB were done in 41 of 65 patients (63.0%) with treatment success in all cases. The susceptible drugs used were 65 (100%) for RFP, 62 (95.4%) for EB, 23 (35.4%) for PZA, 26 (40.0%) for SM, 32 (49.2%) for new quinolone (NQ). 3) The sputum culture conversion rates two months after starting chemotherapy with (N = 16) and without (N = 52) PZA were 13/16 (81.3%) and 31/52 (59.6%), respectively. 4) After the completion of treatment, relapse occurred in 4 patients during follow-up period (1-39 months). The recurrence occurred in 3 out of 20 patients (15%) treated with INH and two susceptible drugs, none out of 13 with three susceptible drugs (0%), 1 out of 20 with INH and three susceptible drugs (5%), and none out of 11 with more than 4 susceptible drugs (0%), and the fact indicates that there was no significant advantage to add INH of usual dose to the regimens. 5) The durations of treatment were not less than 9 months except one case. When 3 or more susceptible drugs were used, the recurrence rate in the group of treatment duration 9-12 months was 0/12 and that in the group of treatment duration more than 12 months was 1/33. Even in the groups without PZA in the initial 2 months of treatment, the recurrence rate in the group of treatment duration 9-12 month was 0/8, and that in the group of treatment duration more than 12 months was 0/22. The fact indicates that 12 months therapy was sufficient irrespective of the use of PZA. 6) One of 5 RFPr-TB patients discontinued treatment by himself. Remaining 4 patients were treated by 4.5 +/- 0.5 susceptible drugs including INH for more than 20 months (21.7 +/- 2.8 months) after sputum culture conversion with the successful result of treatment and no relapses during the followup period for 3-60 months.For INHr-TB, even when PZA can't be used because of adverse effects or resistance, 3 or 4 susceptible drugs regimens including RFP for 12 months were effective. For RFPr-TB, the treatment with 4 or more susceptible drugs for 20 months after sputum culture conversion might be adequate." @default.
• W164057601 created "2016-06-24" @default.
• W164057601 creator A5007329477 @default.
• W164057601 creator A5011615287 @default.
• W164057601 creator A5031699931 @default.
• W164057601 creator A5031777739 @default.
• W164057601 creator A5040638507 @default.
• W164057601 creator A5045804848 @default.
• W164057601 creator A5051423202 @default.
• W164057601 creator A5052865144 @default.
• W164057601 creator A5052928594 @default.
• W164057601 creator A5060224593 @default.
• W164057601 creator A5065225304 @default.
• W164057601 creator A5067563430 @default.
• W164057601 creator A5076963622 @default.
• W164057601 creator A5088100950 @default.
• W164057601 date "2003-10-01" @default.
• W164057601 modified "2023-09-23" @default.
• W164057601 title "[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]." @default.
• W164057601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14621568" @default.
• W164057601 hasPublicationYear "2003" @default.
• W164057601 type Work @default.
• W164057601 sameAs 164057601 @default.
• W164057601 citedByCount "2" @default.
• W164057601 countsByYear W1640576012013 @default.
• W164057601 countsByYear W1640576012023 @default.
• W164057601 crossrefType "journal-article" @default.
• W164057601 hasAuthorship W164057601A5007329477 @default.
• W164057601 hasAuthorship W164057601A5011615287 @default.
• W164057601 hasAuthorship W164057601A5031699931 @default.
• W164057601 hasAuthorship W164057601A5031777739 @default.
• W164057601 hasAuthorship W164057601A5040638507 @default.
• W164057601 hasAuthorship W164057601A5045804848 @default.
• W164057601 hasAuthorship W164057601A5051423202 @default.
• W164057601 hasAuthorship W164057601A5052865144 @default.
• W164057601 hasAuthorship W164057601A5052928594 @default.
• W164057601 hasAuthorship W164057601A5060224593 @default.
• W164057601 hasAuthorship W164057601A5065225304 @default.
• W164057601 hasAuthorship W164057601A5067563430 @default.
• W164057601 hasAuthorship W164057601A5076963622 @default.
• W164057601 hasAuthorship W164057601A5088100950 @default.
• W164057601 hasConcept C126322002 @default.
• W164057601 hasConcept C141071460 @default.
• W164057601 hasConcept C142724271 @default.
• W164057601 hasConcept C167135981 @default.
• W164057601 hasConcept C187212893 @default.
• W164057601 hasConcept C2776228421 @default.
• W164057601 hasConcept C2776967927 @default.
• W164057601 hasConcept C2778607973 @default.
• W164057601 hasConcept C2780459521 @default.
• W164057601 hasConcept C2780499168 @default.
• W164057601 hasConcept C2781069245 @default.
• W164057601 hasConcept C2781413609 @default.
• W164057601 hasConcept C71924100 @default.
• W164057601 hasConcept C72563966 @default.
• W164057601 hasConceptScore W164057601C126322002 @default.
• W164057601 hasConceptScore W164057601C141071460 @default.
• W164057601 hasConceptScore W164057601C142724271 @default.
• W164057601 hasConceptScore W164057601C167135981 @default.
• W164057601 hasConceptScore W164057601C187212893 @default.
• W164057601 hasConceptScore W164057601C2776228421 @default.
• W164057601 hasConceptScore W164057601C2776967927 @default.
• W164057601 hasConceptScore W164057601C2778607973 @default.
• W164057601 hasConceptScore W164057601C2780459521 @default.
• W164057601 hasConceptScore W164057601C2780499168 @default.
• W164057601 hasConceptScore W164057601C2781069245 @default.
• W164057601 hasConceptScore W164057601C2781413609 @default.
• W164057601 hasConceptScore W164057601C71924100 @default.
• W164057601 hasConceptScore W164057601C72563966 @default.
• W164057601 hasIssue "10" @default.
• W164057601 hasLocation W1640576011 @default.
• W164057601 hasOpenAccess W164057601 @default.
• W164057601 hasPrimaryLocation W1640576011 @default.
• W164057601 hasRelatedWork W164057601 @default.
• W164057601 hasRelatedWork W1855501219 @default.
• W164057601 hasRelatedWork W2140173433 @default.
• W164057601 hasRelatedWork W2394344891 @default.
• W164057601 hasRelatedWork W2396308308 @default.
• W164057601 hasRelatedWork W2408929557 @default.
• W164057601 hasRelatedWork W2415538921 @default.
• W164057601 hasRelatedWork W4023405 @default.
• W164057601 hasRelatedWork W4214691822 @default.
• W164057601 hasRelatedWork W2201579144 @default.
• W164057601 hasVolume "78" @default.
• W164057601 isParatext "false" @default.
• W164057601 isRetracted "false" @default.
• W164057601 magId "164057601" @default.
• W164057601 workType "article" @default.